



ABIVAX to Present at BIO-Europe® 2017 – 23rd Annual International Partnering Conference

October 30, 2017

Paris, October 30th, 2017 at 8:00a.m. CET – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral and inflammatory diseases, as well as cancer, today announces that the senior management of ABIVAX will present a corporate development overview at the upcoming BIO-Europe® 2017 – 23rd Annual International Partnering Conference being held November 6-8, 2017 at the CityCube Berlin in Berlin, Germany.

The presentation of Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX is scheduled on Tuesday, November 7th, 2:30pm CET in Room M6 on Level 3.

"This year already witnessed some exceptional milestones in the development of our product portfolio," said Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX. *"In May, we reported first encouraging data from a phase IIa study (ABX464-004) with ABX464, a candidate with the potential to induce a functional cure in HIV patients. In particular, this study showed, for the very first time, that a therapeutic candidate could reduce HIV reservoirs in patients – an effect which was confirmed with a second phase IIa study (ABX464-005) in September. Based on also encouraging preclinical data on the molecule's anti-inflammatory effect in the intestine, we expect to initiate patient recruitment for a proof-of-concept study with ABX464 (ABX464-101) in ulcerative colitis within the next couple of weeks. Moreover, in October we presented data of a preclinical proof-of-concept study showing that our immune enhancer ABX196 significantly increases therapeutic efficacy in oncology - a critical step towards a future partnership in immuno-oncology for ABIVAX. ABIVAX is experiencing an exciting time and I am very much looking forward to discuss our latest developments and achievements with industry experts and key opinion leaders at this important event."*

Companies interested in meeting with ABIVAX at BIO-Europe are requested to send an invitation through the event's [partneringONE@](#)online system. In addition, the Company will also be available for media interviews and background discussions.